Life Science

Retinal Biologics Market Analysis and Global Forecast 2023-2033

$ 1,390.00 – $ 5,520.00

Retinal Biologics Market Research Report: By Drug Class (TNF-α Inhibitor, VEGF-A Antagonist), By Retinal Disorder Type (Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Macular Hole, Uveitis, Others), By Distribution Channel (Hospitals, Retail Pharmacies, Specialty Ophthalmology Clinics), and by Region — Forecast till 2033

Page: 113

Report Published on: October 28, 2024
$ 3,470.00
$ 5,520.00
$ 1,390.00
Clear
Report Code: EBI86425 Categories: ,
Description

Retinal Biologics Market Overview

The Retinal Biologics Market Size is expected to reach USD 49.87 Billion by 2033. The Retinal Biologics industry size accounted for USD 23.65 Billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 8.41% from 2023 to 2033. The retinal biologics market focuses on treatments derived from biological sources to address retinal diseases, including age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. These biologics, such as anti-VEGF (vascular endothelial growth factor) agents, are designed to inhibit abnormal blood vessel growth and leakage in the retina. The market is driven by the increasing prevalence of retinal disorders, advancements in biologic therapies, and growing investment in ophthalmic research. Key players include pharmaceutical and biotechnology companies developing innovative biologic treatments to improve patient outcomes and preserve vision.

Global Retinal Biologics Market Synopsis

Retinal Biologics MarketCOVID-19 Impact Analysis

The COVID-19 pandemic has led to supply chain disruptions leading to supply shortages or lower demand in the Retinal Biologics market. The travel restrictions and social-distancing measures have resulted in a sharp drop in consumer and business spending and this pattern is to continue for some time. The end-user trend and preferences have changed due to the pandemic and have resulted in manufacturers, developers, and service providers adopting various strategies to stabilize the company.

Global Retinal Biologics Market Dynamics

The major factors that have impacted the growth of Retinal Biologics are as follows:

Drivers:

⮚     Advancements in Biologic Therapies

Technological progress and innovation in biologic therapies have led to the development of highly effective treatments for retinal diseases. Anti-VEGF (vascular endothelial growth factor) agents, for example, have shown remarkable success in managing conditions like AMD by inhibiting abnormal blood vessel growth and leakage.

Restraint:

  • Limited Awareness and Diagnosis

In some regions, particularly in developing countries, there is a lack of awareness about retinal diseases and the availability of biologic treatments. Additionally, limited access to advanced diagnostic tools and ophthalmic care can result in underdiagnosis or late diagnosis of retinal conditions, reducing the potential patient pool for biologic therapies.

Opportunity:

⮚     Advancements in Genomic and Personalized Medicine

Emerging research in genomics and personalized medicine offers the potential for developing targeted biologic therapies tailored to individual genetic profiles. This personalized approach can enhance treatment efficacy and reduce side effects, creating opportunities for new biologics that address specific genetic mutations or disease subtypes.

Retinal Biologics Market Segment Overview

Retinal Biologics Market Drug Class AnalysisBy Drug Class

Based on the Drug Class, the market is segmented based on TNF-α Inhibitor, VEGF-A Antagonist. VEGF-A Antagonists dominate due to their proven effectiveness in treating a range of retinal disorders, including Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR).

By Retinal Disorder Type

Based on the Retinal Disorder Type, the market has been divided into Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Macular Hole, Uveitis, Others. Age-related Macular Degeneration (AMD) dominates due to its high prevalence among the aging population and the significant impact of biologic therapies in managing this condition.

By Distribution Channel

Based on Distribution Channel, the market has been divided into Hospitals, Retail Pharmacies, Specialty Ophthalmology Clinics. hospitals typically dominate as the primary distribution channel due to their comprehensive facilities for administering complex biologic treatments and the high volume of patients requiring advanced retinal care.

Global Retinal Biologics Market Regional Analysis

Based on region, the market has been divided into North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America. The area of North America is anticipated to dominate the market for the usage of Retinal Biologics, followed by those in Asia-Pacific and Europe.

Global Retinal Biologics Market Regional AnalysisRetinal Biologics North America Market

North America dominates the Retinal Biologics market due to several factors. In 2022, the Retinal Biologics Market in North America held a 45.80% market share. One of the continuing problems for the US and other countries is thought to be eye ailments. America accounted for the largest market because to the rising rates of uveitis, diabetic retinopathy, macular degeneration, and other eye illnesses. Approximately 196 million people worldwide currently suffer from macular degeneration; by 2040, that figure is expected to increase to 288 million. Due to the increasing number of new cases of eye diseases in this area, there is a growing need for retinal biologics products.

Retinal Biologics Asia Pacific Market

The Asia-Pacific region has been witnessing remarkable growth in recent years. From 2023 to 2032, the Asia Pacific retinal biologics market is anticipated to grow at a substantial rate. This region has seen a rise in market growth as a result of increased research into the development of retinal biologics and the rising incidence of eye disorders. Furthermore, the aging population is driving the demand for retinal biologics.

Competitive Landscape

The competitive landscape includes key players (tier 1, tier 2, and local) having a presence across the globe. Companies such as Novartis AG, Hoffmann La Roche Ltd, ABBVIE INC., MeiraGTx Limited, and OncoGene are some of the leading players in the global  Retinal Biologics Industry. These players have adopted partnership, acquisition, expansion, and new product development, among others as their key strategies.

Key Market Players:

  • Novartis AG
  • Hoffmann La Roche Ltd
  • ABBVIE INC.
  • MeiraGTx Limited
  • OncoGene
  • Johnson & Johnson
  • Allergan
  • Bristol-Myers Squibb Company
  • Regeneron
  • Oxurion NV

Key development:

In September 2022, Johnson & Johnson advanced its retinal biologics portfolio by announcing positive results from clinical trials of its new anti-VEGF treatment, enhancing its position in the retinal disease market.

Scope of the Report

Global Retinal Biologics Market, by Drug Class
  • TNF-α Inhibitor
  • VEGF-A Antagonist
Global Retinal Biologics Market, by Retinal Disorder Type
  • Age-related Macular Degeneration (AMD)
  • Diabetic Retinopathy (DR)
  • Diabetic Macular Edema (DME)
  • Macular Hole
  • Uveitis
  • Others
Global Retinal Biologics Market, by Distribution Channel
  • Hospitals
  • Retail Pharmacies
  • Specialty Ophthalmology Clinics
Global Retinal Biologics Market, by Region
  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Benelux
    • Nordic
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • Indonesia
    • Austalia
    • Malaysia
    • India
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • South Africa
    • Rest of Middle East & Africa
Parameters Indicators
Market Size 2033: USD 49.87 Billion
CAGR (2023-2033) 8.41%
Base year 2022
Forecast Period 2023-2033
Historical Data 2021 (2017 to 2020 On Demand)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Key Segmentations Drug Class, Retinal Disorder Type, Distribution Channel
Geographies Covered North America, Europe, Asia-Pacific, South America, Middle East, Africa
Key Vendors Novartis AG, Hoffmann La Roche Ltd, ABBVIE INC., MeiraGTx Limited, OncoGene, Johnson & Johnson, Allergan, Bristol-Myers Squibb Company, Regeneron, Oxurion NV.
Key Market Opportunities ·       Technological advances and new product approvals
Key Market Drivers ·       Growing number of cases with ophthalmic disorders causing chronic retinal diseases across the globe and increasing prevalence of retinal vein occlusion (RVO) and age-related macular degeneration

 

REPORT CONTENT BRIEF:

  • High-level analysis of the current and future Retinal Biologics Industry trends and opportunities
  • Detailed analysis of current market drivers, restraining factors, and opportunities analysis in the future
  • Historical market size for the year 2021, and forecast from 2023 to 2033
  • Retinal Biologics market share analysis for each segment
  • Competitor analysis with a comprehensive insight into its product segment, financial strength, and strategies adopted.
  • Identifies key strategies adopted by the key players including new product development, mergers and acquisitions, joint ventures, collaborations, and partnerships.
  • To identify and understand the various factors involved in the global Retinal Biologics market affected by the pandemic
  • To provide year-on-year growth from 2022 to 2033
  • To provide short-term, long-term, and overall CAGR comparison from 2022 to 2033.
  • Provide Total Addressable Market (TAM) for the Global Retinal Biologics Market.

Frequently Asked Questions (FAQ)

The global Retinal Biologics market is growing at a CAGR of ~8.41% over the next 10 years

Asia Pacific is expected to register the highest CAGR during 2023-2033

North America holds the largest share in 2022

Novartis AG, Hoffmann La Roche Ltd, ABBVIE INC., MeiraGTx Limited, OncoGene, Johnson & Johnson, Allergan, Bristol-Myers Squibb Company, Regeneron, Oxurion NV

Yes, we offer 16 hours of analyst support to solve the queries

Yes, we do provide regional as well as country-level reports. Other than this we also provide a sectional report. Please get in contact with our sales representatives.

For more details mail us at

Ask a question / additional requirement

Press Release

Table of Content

Table of Content

CHAPTER 1.               Executive Summary

CHAPTER 2.               Scope of the Study

2.1.       Market Definition

2.2.       Market Scope & Segmentation

2.2.1.        Objective of Report

CHAPTER 3.               Evolve BI Methodology

3.1.       Data Collection & Validation Approach

3.2.       Market Size Estimation and Forecast

CHAPTER 4.               Exclusive Analysis

4.1.       Market Opportunity Score

4.1.1.        Drug Class Segement – Market Opportunity Score

4.1.2.        Retinal Disorder Type Segment – Market Opportunity Score

4.1.3.        Distribution Channel Segment – Market Opportunity Score

4.2.       Key Market Influencing Indicators

CHAPTER 5.               Market Insights and Trends

5.1.       Value Chain Analysis

5.1.1.        Raw Material

5.1.2.        Manufacturing Process

5.1.3.        Distribution Channel

5.1.4.        End User

5.2.       Porter’s Five Forces Analysis

5.2.1.        Bargaining Power of Buyers

5.2.2.        Bargaining Power of Suppliers

5.2.3.        Threat of New Entrant

5.2.4.        Threat of Substitute

5.2.5.        Industry Rivalry

5.3.       COVID-19 Impact and Post COVID Scenario on Retinal Biologics Market

5.3.1.        Impact of COVID-19

5.3.2.        Government Support and Industry Revival Policies

5.3.3.        Measures Taken by Companies to Mitigate Negative Impact

5.3.4.        Post COVID Trend

CHAPTER 6.               MArket Dynamics

6.1.       Introduction

6.2.       Drivers

6.2.1.        Driver 1

6.2.2.        Driver 2

6.2.3.        Driver 3

6.3.       Restraints

6.3.1.        Restraint 1

6.3.2.        Restraint 2

6.4.       Opportunity

6.4.1.        Opportunity 1

CHAPTER 7.               Global Retinal Biologics Market, By Drug Class

7.1.       Introduction

7.1.1. TNF-α Inhibitor

7.1.2. VEGF-A Antagonist

CHAPTER 8.               Global Retinal Biologics Market, By Retinal Disorder Type

8.1.       Introduction

8.1.1. Age-related Macular Degeneration (AMD)

8.1.2. Diabetic Retinopathy (DR)

8.1.3. Diabetic Macular Edema (DME)

8.1.4. Macular Hole

8.1.5. Uveitis

8.1.6. Others

CHAPTER 9.               Global Retinal Biologics Market, By Distribution Channel

9.1.       Introduction

9.1.1. Hospitals

9.1.2. Retail Pharmacies

9.1.3. Specialty Ophthalmology Clinics

CHAPTER 10.             Global Retinal Biologics Market, By Region

10.1.     Introduction

10.2.     NORTH AMERICA

10.2.1.      North America: Market Size and Forecast, By Country, 2023 – 2033 ($ Million)

10.2.2.      North America: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.2.3.      North America: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.2.4.      North America: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.2.5.      US

10.2.5.1.       US: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.2.5.2.       US: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.2.5.3.       US: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.2.6.      CANADA

10.2.6.1.       Canada: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.2.6.2.       Canada: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.2.6.3.       Canada: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.2.7.      MEXICO

10.2.7.1.       Mexico: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.2.7.2.       Mexico: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.2.7.3.       Mexico: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.3.     Europe

10.3.1.      Europe: Market Size and Forecast, By Country, 2023 – 2033 ($ Million)

10.3.2.      Europe: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.3.3.      Europe: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.3.4.      Europe: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.3.5.      U.K.

10.3.5.1.       U.K.: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.3.5.2.       U.K.: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.3.5.3.       U.K.: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.3.6.      GERMANY

10.3.6.1.       Germany: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.3.6.2.       Germany: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.3.6.3.       Germany: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.3.7.      FRANCE

10.3.7.1.       France: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.3.7.2.       France: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.3.7.3.       France: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.3.8.      ITALY

10.3.8.1.       Italy: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.3.8.2.       Italy: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.3.8.3.       Italy: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.3.9.          SPAIN

10.3.9.1.       Spain: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.3.9.2.       Spain: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.3.9.3.       Spain: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.3.10.        BENELUX

10.3.10.1.    BeNeLux: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.3.10.2.    BeNeLux: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.3.10.3.    BeNeLux: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.3.11.        RUSSIA

10.3.11.1.    Russia: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.3.11.2.    Russia: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.3.11.3.    Russia: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.3.12.        REST OF EUROPE

10.3.12.1.    Rest of Europe: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.3.12.2.    Rest of Europe: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.3.12.3.    Rest of Europe: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.4.     Asia Pacific

10.4.1.      Asia Pacific: Market Size and Forecast, By Country, 2023 – 2033 ($ Million)

10.4.2.      Asia Pacific: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.4.3.      Asia Pacific: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.4.4.      Asia Pacific: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.4.5.      CHINA

10.4.5.1.       China: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.4.5.2.       China: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.4.5.3.       China: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.4.6.      JAPAN

10.4.6.1.       Japan: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.4.6.2.       Japan: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.4.6.3.       Japan: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.4.7.      INDIA

10.4.7.1.       India: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.4.7.2.       India: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.4.7.3.       India: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.4.8.      SOUTH KOREA

10.4.8.1.       South Korea: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.4.8.2.       South Korea: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.4.8.3.       South Korea: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.4.9.          THAILAND

10.4.9.1.       Thailand: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.4.9.2.       Thailand: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.4.9.3.       Thailand: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.4.10.        INDONESIA

10.4.10.1.    Indonesia: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.4.10.2.    Indonesia: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.4.10.3.    Indonesia: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.4.11.        MALAYSIA

10.4.11.1.    Malaysia: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.4.11.2.    Malaysia: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.4.11.3.    Malaysia: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.4.12.        AUSTRALIA

10.4.12.1.    Australia: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.4.12.2.    Australia: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.4.12.3.    Australia: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.4.13.        REST FO ASIA PACIFIC

10.4.13.1.    Rest fo Asia Pacific: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.4.13.2.    Rest fo Asia Pacific: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.4.13.3.    Rest fo Asia Pacific: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.5.     South America

10.5.1.      South America: Market Size and Forecast, By Country, 2023 – 2033 ($ Million)

10.5.2.      South America: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.5.3.      South America: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.5.4.      South America: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.5.5.      BRAZIL

10.5.5.1.       Brazil: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.5.5.2.       Brazil: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.5.5.3.       Brazil: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.5.6.      ARGENTINA

10.5.6.1.       Argentina: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.5.6.2.       Argentina: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.5.6.3.       Argentina: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.5.7.      REST OF SOUTH AMERICA

10.5.7.1.       Rest of South America: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.5.7.2.       Rest of South America: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.5.7.3.       Rest of South America: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.6.     Middle East & Africa

10.6.1.      Middle East & Africa: Market Size and Forecast, By Country, 2023 – 2033 ($ Million)

10.6.2.      Middle East & Africa: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.6.3.      Middle East & Africa: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.6.4.      Middle East & Africa: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.6.5.      SAUDI ARABIA

10.6.5.1.       Saudi Arabia: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.6.5.2.       Saudi Arabia: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.6.5.3.       Saudi Arabia: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.6.6.      UAE

10.6.6.1.       UAE: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.6.6.2.       UAE: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.6.6.3.       UAE: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.6.7.      EGYPT

10.6.7.1.       Egypt: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.6.7.2.       Egypt: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.6.7.3.       Egypt: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.6.8.      SOUTH AFRICA

10.6.8.1.       South Africa: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.6.8.2.       South Africa: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.6.8.3.       South Africa: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

10.6.9.          REST OF MIDDLE EAST & AFRICA

10.6.9.1.       Rest of Middle East & Africa: Market Size and Forecast, By Drug Class, 2023 – 2033 ($ Million)

10.6.9.2.       Rest of Middle East & Africa: Market Size and Forecast, By Retinal Disorder Type, 2023 – 2033 ($ Million)

10.6.9.3.       Rest of Middle East & Africa: Market Size and Forecast, By Distribution Channel, 2023 – 2033 ($ Million)

CHAPTER 12.             Competitive Landscape

12.1.     Competitior Benchmarking 2023

12.2.     Market Share Analysis

12.3.     Key Developments Analysis By Top 5 Companies

12.4.     Market Share Acquisition Strategies: Analysis of Key Approaches Employed by Top Players

CHAPTER 13.             Company Profiles

13.1.     Novartis AG

13.1.1.      Business Overview

13.1.2.      Financial Analysis

13.1.2.1.       Business Segment Revenue, 2020, 2021, 2022, $ Million

13.1.2.2.       Geographic Revenue Mix, 2022 (% Share)

13.1.3.      Product Portfolio

13.1.4.      Recent Development and Strategies Adopted

13.1.5.      SWOT Analysis

13.2.     Hoffmann La Roche Ltd

13.3.     ABBVIE INC.

13.4.     MeiraGTx Limited

13.5.     OncoGene

13.6.     Johnson & Johnson

13.7.     Allergan

13.8.     Bristol-Myers Squibb Company

13.9.     Regeneron

13.10.  Genie AI Ltd

Connect to Analyst

Connect to Analyst

Research Methodology

Research Methodology

Our Most Viewed Report and gain instant expertise

Life Science
$ 3,470.00
$ 5,520.00
$ 1,390.00
Clear

Antibiotics Market Analysis and Global Forecast 2023-2033

$ 1,390.00 – $ 5,520.00
Antibiotics Market Research Report: By Class (Beta Lactam & Beta Lactamase Inhibitors, Quinolone, Macrolide, Others), By Drug Origin (Natural, Semisynthetic, Synthetic), By Spectrum of Activity (Broad-spectrum Antibiotic, Narrow-spectrum Antibiotic), and by Region — Forecast till 2033. Page: 167
Select options This product has multiple variants. The options may be chosen on the product page
Quick view
Life Science
$ 3,470.00
$ 5,520.00
$ 1,390.00
Clear

Blood Product Market Analysis and India Forecast 2023-2033

$ 1,390.00 – $ 5,520.00
Blood Product Market Research Report: Information By Type (Coagulation Factor, Immune Globulin, Albumin), By Application (Surgery, Therapy, Immunity), and by Region — Forecast till 2033 Page: 77
Select options This product has multiple variants. The options may be chosen on the product page
Quick view
Life Science
$ 3,470.00
$ 5,520.00
$ 1,390.00
Clear

Blood Purification Equipment Market Analysis and Global Forecast 2023-2033

$ 1,390.00 – $ 5,520.00
Blood Purification Equipment Market Research Report: By Product Type (Portable, Stationary), By Indication (Sepsis, Renal Diseases, Others), By End User (Hospitals and Clinics, Dialysis Centers, Others), and by Region — Forecast till 2033 Page: 165
Select options This product has multiple variants. The options may be chosen on the product page
Quick view
Life Science
$ 3,470.00
$ 5,520.00
$ 1,390.00
Clear

Cough Syrup Market Analysis and Global Forecast 2023-2033

$ 1,390.00 – $ 5,520.00
Cough Syrup Market Research Report: Information By Product Type (Combination Drugs, Individuals), By Category (Cough Suppressants, Expectorants), and by Region — Forecast till 2033 Page: 165
Select options This product has multiple variants. The options may be chosen on the product page
Quick view
Life Science
$ 3,470.00
$ 5,520.00
$ 1,390.00
Clear

Gene Therapy Cell Culture Media Market Analysis and Global Forecast 2023-2033

$ 1,390.00 – $ 5,520.00
Gene Therapy Cell Culture Media Market Research Report: Information By Product Type (Media, Viral Vectors), By Application (Biotechnology & Pharmaceutical Industry, Research Laboratory, Academic Institute, Others), and by Region — Forecast till 2033 Page: 164
Select options This product has multiple variants. The options may be chosen on the product page
Quick view
Life Science
$ 3,470.00
$ 5,520.00
$ 1,390.00
Clear

Track and Trace Solutions Market Analysis and Global Forecast 2023-2033

$ 1,390.00 – $ 5,520.00

Track and Trace Solutions Market Research Report: Information By Product Type (Hardware Components, Software, Standalone Platforms, Tracking, Tracing and Reporting Solutions), By Application (Serialization Solutions, Medical Devices Serialization Aggregation Solution), and by Region — Forecast till 2033

Page: 163
Select options This product has multiple variants. The options may be chosen on the product page
Quick view
Life Science
$ 3,470.00
$ 5,520.00
$ 1,390.00
Clear

Vaccine Market Analysis and Global Forecast 2023-2033

$ 1,390.00 – $ 5,520.00

Vaccine Market Research Report: Information By Type (Monovalent Vaccines, Multivalent Vaccines), By Indication (Pneumococcal Diseases, DTP, HPV, Influenza, Meningococcal Disease, Polio, Hepatitis, Rotavirus, MMR, Varicella, Herpes Zoster, Ebola, COVID, Others), By Application (Conjugate Vaccines, Inactivated & Subunit, Live Attenuated, Recombinant Vaccines), and by Region — Forecast till 2033

Report Code: EB_LS_450 | Page: 219
Select options This product has multiple variants. The options may be chosen on the product page
Quick view
Life Science
$ 3,470.00
$ 5,520.00
$ 1,390.00
Clear

Wearable Patch Market Analysis and Global Forecast 2023-2033

$ 1,390.00 – $ 5,520.00

Wearable Patch Market Research Report: Information By Technology Outlook(Regular Wearable, Connected Wearable), By Application (Clinical, Non-clinical), and by Region — Forecast till 2033.

Page: 153
Select options This product has multiple variants. The options may be chosen on the product page
Quick view